MRVI
Price
$7.05
Change
-$0.02 (-0.28%)
Updated
Oct 23, 11:15 AM (EDT)
Capitalization
1.05B
12 days until earnings call
Intraday BUY SELL Signals
NVCT
Price
$20.33
Change
-$0.56 (-2.68%)
Updated
Oct 23, 11:11 AM (EDT)
Capitalization
681.93M
11 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MRVI vs NVCT

MRVI vs NVCT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MRVI vs. NVCT commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRVI is a Hold and NVCT is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MRVI with price predictions
Oct 22, 2026

Aroon Indicator for MRVI shows an upward move is likely

MRVI's Aroon Indicator triggered a bullish signal on October 13, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 172 similar instances where the Aroon Indicator showed a similar pattern. In 158 of the 172 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +8.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where MRVI advanced for three days, in 205 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MRVI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for MRVI moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 27 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 87%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on October 22, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MRVI as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.

The Moving Average Convergence Divergence Histogram (MACD) for MRVI turned negative on October 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

MRVI moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for MRVI crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MRVI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.148) is normal, around the industry mean (2.973). P/E Ratio (-13.340) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.785) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. MRVI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 42 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MRVI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for NVCT with price predictions
Oct 22, 2026

NVCT's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NVCT turned positive on October 21, 2026. Looking at past instances where NVCT's MACD turned positive, the stock continued to rise in 41 of 44 cases over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on NVCT as a result. In 93 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

Following a +1.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCT advanced for three days, in 250 of 282 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

NVCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

NVCT moved below its 50-day moving average on October 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVCT crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

The Aroon Indicator for NVCT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. NVCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 60 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NVCT's P/B Ratio (75.086) is slightly higher than the industry average of (2.973). P/E Ratio (-15.826) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
MRVI: Fundamental Ratings
MRVI
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
42
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MRVINVCT
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
88%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 1 day ago
89%
Declines
ODDS (%)
Bearish Trend 11 days ago
83%
Bearish Trend 10 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (MRVI: $7.07 vs. NVCT: $20.89)
Brand notoriety: MRVI and NVCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MRVI: 104% vs. NVCT: 48%
Market capitalization -- MRVI: $1.05B vs. NVCT: $681.93M
MRVI [@Biotechnology] is valued at $1.05B. NVCT’s [@Biotechnology] market capitalization is $681.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRVI’s FA Score shows that 1 FA rating(s) are green while NVCT’s FA Score has 0 green FA rating(s).

  • MRVI’s FA Score: 1 green, 4 red.
  • NVCT’s FA Score: 0 green, 5 red.
According to our system of comparison, MRVI is a better buy in the long-term than NVCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRVI’s TA Score shows that 3 TA indicator(s) are bullish while NVCT’s TA Score has 4 bullish TA indicator(s).

  • MRVI’s TA Score: 3 bullish, 7 bearish.
  • NVCT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NVCT is a better buy in the short-term than MRVI.

Price Growth

MRVI (@Biotechnology) experienced а 0.00% price change this week, while NVCT (@Biotechnology) price change was +10.35% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.31%. For the same industry, the average monthly price growth was -16.25%, and the average quarterly price growth was -16.62%.

Reported Earning Dates

MRVI is expected to report earnings on Nov 04, 2026.

NVCT is expected to report earnings on Nov 03, 2026.

Industries' Descriptions

@Biotechnology (+1.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
MRVI
Daily Signal:
Gain/Loss:
NVCT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

MRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRVI has been loosely correlated with MRNA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if MRVI jumps, then MRNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRVI
1D Price
Change %
MRVI100%
-6.61%
MRNA - MRVI
46%
Loosely correlated
-17.57%
BNTX - MRVI
42%
Loosely correlated
-1.77%
RXRX - MRVI
41%
Loosely correlated
-1.65%
TWST - MRVI
40%
Loosely correlated
-9.16%
NVAX - MRVI
39%
Loosely correlated
-9.26%
More

NVCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVCT has been loosely correlated with UNCY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCT jumps, then UNCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCT
1D Price
Change %
NVCT100%
+0.92%
UNCY - NVCT
51%
Loosely correlated
+1.81%
DFTX - NVCT
37%
Loosely correlated
+1.44%
ABSI - NVCT
34%
Loosely correlated
-6.67%
VYGR - NVCT
33%
Loosely correlated
-7.92%
MRVI - NVCT
33%
Poorly correlated
-6.61%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AXON414.6012.00
+2.98%
Axon Enterprise
IBOC67.281.19
+1.80%
International Bancshares Corp
PDYN3.65-0.04
-1.08%
Palladyne AI Corp
GRNQ7.15-0.25
-3.38%
Greenpro Capital Corp
UMAC16.27-0.71
-4.18%
Unusual Machines